David Dilworth,Ronan P. Hanley,Renato Ferreira de Freitas,Abdellah Allali-Hassani,Mengqi Zhou,Naimee Mehta,Matthew R. Marunde,Suzanne Ackloo,Edyta Marcon,Fengling Li,Irene Chau,Albina Bolotokova,Su Qin,Ming Lei,Yanli Liu,Magdalena M Szewczyk,Aiping Dong,Sina Kazemzadeh,Tigran Abramyan,Irina K Popova,Nathan W Hall,Matthew J Meiners,Marcus A Cheek,Elisa Gibson,Dmitri Kireev,Jack F. Greenblatt,Michael-C. Keogh,Jinrong Min,Peter J. Brown,Masoud Vedadi,Cheryl H. Arrowsmith,Dalia Barsyte-Lovejoy,Lindsey I James,Matthieu Schapira

Abstract:NSD2 is the primary enzyme responsible for the dimethylation of lysine 36 of histone 3 (H3K36me2), a mark associated with active gene transcription and intergenic DNA methylation. In addition to a methyltransferase domain, NSD2 harbors two PWWP and five PHD domains believed to serve as chromatin reading modules, but their exact function in the regulation of NSD2 activity remains underexplored. Here we report a first-in-class chemical probe targeting the N-terminal PWWP (PWWP1) domain of NSD2. UNC6934 binds potently (Kd of 91 ± 8 nM) to PWWP1, antagonizes its interaction with nucleosomal H3K36me2, and selectively engages endogenous NSD2 in cells. Crystal structures show that UNC6934 occupies the canonical H3K36me2-binding pocket of PWWP1 which is juxtaposed to the DNA-binding surface. In cells, UNC6934 induces accumulation of endogenous NSD2 in the nucleolus, phenocopying the localization defects of NSD2 protein isoforms lacking PWWP1 as a result of translocations prevalent in multiple myeloma. Mutation of other NSD2 chromatin reader domains also increases NSD2 nucleolar localization, and enhances the effect of UNC6934 . Finally we identified two C-terminal nucleolar localization sequences in NSD2 that appear to drive nucleolar accumulation when one or more chromatin reader domains are disabled. These data support a model in which NSD2 chromatin engagement is achieved in a cooperative manner and subcellular localization is controlled by multiple competitive structural determinants. This chemical probe and the accompanying negative control, UNC7145 , will be useful tools in defining NSD2 biology. ### Competing Interest Statement EpiCypher is a commercial developer and supplier of reagents and platforms used in this study: recombinant semi-synthetic modified nucleosomes (dNucs) and the dCypher binding assay. * Abbreviations used : DCM : Dichloromethane DIPEA : N,N -Diisopropylethylamine DMAP : 4-(Dimethylamino)pyridine DMF : N,N -Dimethylformamide DMSO : Dimethylsulfoxide EDC : N -(3-Dimethylaminopropyl)- N’ -ethylcarbodiimide hydrochloride HOAt : 1-Hydroxy-7-azabenzotriazole LCMS : Liquid Chromatography-Mass Spectrometry NMR : Nuclear Magnetic Resonance TCFH : Chloro- N,N,N’,N’ -tetramethylformamidinium hexafluorophosphate TFA : 2,2,2-Trifluoroacetic acid THF : Tetrahydrofuran

Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader

Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs

Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors Using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (Sam)-Dependent Methyltransferase Family.

Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors

Covalent inhibition of NSD1 histone methyltransferase

Identification of potential methyltransferase NSD2 enzymatic inhibitors through a multi-step structure-based drug design

Abstract 4517: Novel chemical degraders targeting NSD2 in head and neck squamous cell carcinoma (HNSCC)

Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies

Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity

Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands

Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2

Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones As Potent NSD2 Inhibitors

Recruitment of FBXO22 for targeted degradation of NSD2

Discovery of LLC355 as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1

Pharmacological targeting of a PWWP domain demonstrates cooperative control of NSD2 localization

A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells

Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression

Discovery of electrophilic degraders that exploit SNAr chemistry